Abstract

BackgroundImmune checkpoint blockade (ICB) has been approved for the treatment of triple-negative breast cancer (TNBC), since it significantly improved the progression-free survival (PFS). However, only about 10% of TNBC patients could achieve the complete response (CR) to ICB because of the low response rate and potential adverse reactions to ICB.MethodsOpen datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were downloaded to perform an unsupervised clustering analysis to identify the immune subtype according to the expression profiles. The prognosis, enriched pathways, and the ICB indicators were compared between immune subtypes. Afterward, samples from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset were used to validate the correlation of immune subtype with prognosis. Data from patients who received ICB were selected to validate the correlation of the immune subtype with ICB response. Machine learning models were used to build a visual web server to predict the immune subtype of TNBC patients requiring ICB.ResultsA total of eight open datasets including 931 TNBC samples were used for the unsupervised clustering. Two novel immune subtypes (referred to as S1 and S2) were identified among TNBC patients. Compared with S2, S1 was associated with higher immune scores, higher levels of immune cells, and a better prognosis for immunotherapy. In the validation dataset, subtype 1 samples had a better prognosis than sub type 2 samples, no matter in overall survival (OS) (p = 0.00036) or relapse-free survival (RFS) (p = 0.0022). Bioinformatics analysis identified 11 hub genes (LCK, IL2RG, CD3G, STAT1, CD247, IL2RB, CD3D, IRF1, OAS2, IRF4, and IFNG) related to the immune subtype. A robust machine learning model based on random forest algorithm was established by 11 hub genes, and it performed reasonably well with area Under the Curve of the receiver operating characteristic (AUC) values = 0.76. An open and free web server based on the random forest model, named as triple-negative breast cancer immune subtype (TNBCIS), was developed and is available from https://immunotypes.shinyapps.io/TNBCIS/.ConclusionTNBC open datasets allowed us to stratify samples into distinct immunotherapy response subgroups according to gene expression profiles. Based on two novel subtypes, candidates for ICB with a higher response rate and better prognosis could be selected by using the free visual online web server that we designed.

Highlights

  • Breast cancer (BC) is the most prevalent cancer in women worldwide, and the number of new cases diagnosed was 2.3 million in 2020 [1]

  • Our study might contribute to explore the heterogeneity among triple-negative breast cancer (TNBC) patients and provide a way to identify the appropriate patient for the immunotherapies

  • The results indicated that immune checkpoints and T-cell cytotoxicity factors were significantly higher in subtype1, and epithelial–mesenchymal transition (EMT) biomarkers were higher in subtype 2 (Figure 3B)

Read more

Summary

Introduction

Breast cancer (BC) is the most prevalent cancer in women worldwide, and the number of new cases diagnosed was 2.3 million in 2020 [1]. The Food and Drug Administration (FDA) granted the combination of chemotherapy and Pembrolizumab for the treatment of PD-L1+ metastatic TNBC patients [9]. This approval was based on a randomized, double-blind, phase III, TNBC study (NCT02819518), in which the progression-free survival (PFS) was significantly higher in the Pembrolizumab– Chemotherapy arm (9.7 months) than in the placebo arm (5.6 months) (hazard ratio, 0.65; 95% confidence interval, 0.49–0.86, p = 0.0012) [10]. Immune checkpoint blockade (ICB) has been approved for the treatment of triple-negative breast cancer (TNBC), since it significantly improved the progression-free survival (PFS). Only about 10% of TNBC patients could achieve the complete response (CR) to ICB because of the low response rate and potential adverse reactions to ICB

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call